Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions

por Hanke, Nina, Gómez-Mantilla, José David, Ishiguro, Naoki, Stopfer, Peter, Nock, Valerie
Publicado 2021

Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes

por Baron, Kyle T., Macha, Sreeraj, Broedl, Uli C., Nock, Valerie, Retlich, Silke, Riggs, Matthew
Publicado 2016

A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug–Drug Interaction Studies

por Hanke, Nina, Türk, Denise, Selzer, Dominik, Wiebe, Sabrina, Fernandez, Éric, Stopfer, Peter, Nock, Valerie, Lehr, Thorsten
Publicado 2020

A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclo...

por Kanacher, Tobias, Lindauer, Andreas, Mezzalana, Enrica, Michon, Ingrid, Veau, Celine, Mantilla, Jose David Gómez, Nock, Valerie, Fleury, Angèle
Publicado 2020

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions

por Britz, Hannah, Hanke, Nina, Taub, Mitchell E., Wang, Ting, Prasad, Bhagwat, Fernandez, Éric, Stopfer, Peter, Nock, Valerie, Lehr, Thorsten
Publicado 2020

Significant impact of time-of-day variation on metformin pharmacokinetics

por Türk, Denise, Scherer, Nina, Selzer, Dominik, Dings, Christiane, Hanke, Nina, Dallmann, Robert, Schwab, Matthias, Timmins, Peter, Nock, Valerie, Lehr, Thorsten
Publicado 2023

A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug–Drug–Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals

por Hanke, Nina, Türk, Denise, Selzer, Dominik, Ishiguro, Naoki, Ebner, Thomas, Wiebe, Sabrina, Müller, Fabian, Stopfer, Peter, Nock, Valerie, Lehr, Thorsten
Publicado 2020

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes

por Johnston, Curtis K., Eudy-Byrne, Rena J., Elmokadem, Ahmed, Nock, Valerie, Marquard, Jan, Soleymanlou, Nima, Riggs, Matthew M., Liesenfeld, Karl-Heinz
Publicado 2021

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

por Perkins, Bruce A., Soleymanlou, Nima, Rosenstock, Julio, Skyler, Jay S., Laffel, Lori M., Liesenfeld, Karl‐Heinz, Neubacher, Dietmar, Riggs, Matthew M., Johnston, Curtis K., Eudy‐Byrne, Rena J., Elmokadem, Ahmed, George, Jyothis T., Marquard, Jan, Nock, Valerie
Publicado 2020

Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences

por Lippert, Jörg, Burghaus, Rolf, Edginton, Andrea, Frechen, Sebastian, Karlsson, Mats, Kovar, Andreas, Lehr, Thorsten, Milligan, Peter, Nock, Valerie, Ramusovic, Sergej, Riggs, Matthew, Schaller, Stephan, Schlender, Jan, Schmidt, Stephan, Sevestre, Michaël, Sjögren, Erik, Solodenko, Juri, Staab, Alexander, Teutonico, Donato
Publicado 2019